Markets:

Overview

News

Currencies

International

Treasuries

Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

9.930 -0.090 (-0.90%)

Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Amicus Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Amicus Therapeutics Inc (NASDAQ:FOLD) Q3 2025 Earnings: A Landmark Quarter with Strong Profitability Beat ↗

November 04, 2025

Amicus Therapeutics (FOLD) beats Q3 2025 earnings estimates with strong revenue growth and a major milestone in profitability, driving positive market momentum.

Via Chartmill

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

This CSX Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

September 18, 2025

Via Benzinga

Amicus (FOLD) Q2 Revenue Jumps 22% ↗

August 01, 2025

Via The Motley Fool

Topics Intellectual Property

Amicus Therapeutics Inc (NASDAQ:FOLD) Beats Q2 2025 Earnings and Revenue Estimates, Shares Rise in Pre-Market Trading ↗

July 31, 2025

Amicus Therapeutics (FOLD) beats Q2 2025 revenue and EPS estimates, driven by strong growth in Galafold and Pompe disease therapies, sparking a 2.77% pre-market rally.

Via Chartmill

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

Amicus Therapeutics Earnings Preview ↗

April 30, 2025

Via Benzinga

Earnings Scheduled For February 19, 2025 ↗

February 19, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On Amicus Therapeutics Through 6 Analysts ↗

January 13, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 01, 2025

Via Benzinga

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? ↗

December 13, 2024

Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks.

Via Benzinga

A Closer Look at 8 Analyst Recommendations For Amicus Therapeutics ↗

November 12, 2024

Via Benzinga

The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts ↗

November 12, 2024

Via Benzinga

Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings) ↗

November 12, 2024

Via Benzinga

Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights ↗

November 07, 2024

Via Benzinga

Expert Outlook: Amicus Therapeutics Through The Eyes Of 4 Analysts ↗

October 11, 2024

Via Benzinga

Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts ↗

May 14, 2024

Via Benzinga

The Analyst Landscape: 4 Takes On Amicus Therapeutics ↗

December 19, 2023

Via Benzinga

Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug ↗

October 17, 2024

Amicus Therapeutics enters a license agreement with Teva Pharmaceuticals resolving patent litigation over a generic version of Galafold. Teva may market its version starting in 2037, pending FDA...

Via Benzinga

Topics Intellectual Property Lawsuit

Travelers Posts Upbeat Results, Joins Iridium Communications, Snap-on And Other Big Stocks Moving Higher On Thursday ↗

October 17, 2024

Via Benzinga

FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today. ↗

May 14, 2024

Via Benzinga

FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024 ↗

May 09, 2024

FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

Amicus Therapeutics Stock Sees RS Rating Improve To 74 ↗

March 05, 2024

In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday.

Via Investor's Business Daily

Amicus Therapeutics Stock Sees Improved Relative Strength Rating ↗

February 09, 2024

In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday.

Via Investor's Business Daily

7 Stocks Most Likely to Follow in WeWork’s Woeful Footsteps ↗

November 15, 2023

These troubled stocks to sell look even worse following WeWork's bankruptcy and will only hurt holders the longer they hold on.

Via InvestorPlace

Topics Bankruptcy

Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session ↗

September 29, 2023

U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Amicus Therapeutics Drug Scores FDA Approval For Rare Inherited Pompe Disease ↗

September 28, 2023

The FDA has approved Amicus Therapeutics' (NASDAQ: FOLD) Pombiliti (cipaglucosidase alfa-atga)+Opfolda (miglustat) 65mg capsules for Pompe disease.

Via Benzinga

Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark ↗

September 28, 2023

Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level.

Via Investor's Business Daily

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.